Vir Biotechnology, Inc. VIR
Set alert
As of Nov 2, 10:41 AM ET
- YTD
- +86.99%
- 1 year
- +89.19%
- Open
- 11.36
- Prev close
- 11.30
- Mkt cap
- 1.91B
- Vol
- 140.15K
- Avg vol
- 1.92M
- EPS
- -1.76
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 11.25
- High
- 11.55
- Forward P/E
- -4.54
- Beta
- 1.59
- Short ratio
- 7.15
- Inst. own
- 84.42%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 10.90
- 200-d avg
- 9.50
- 1y target
- 21.00
1M chart
Events in this range
- Oct 7, 2026Rating: HC Wainwright & Co. · Buy → Buy
Signals (11)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 27, 2026 | 6 days ago |
| SMA: Bullish | Oct 26, 2026 | 1 week ago |
| SMA: Bullish | Oct 23, 2026 | 1 week ago |
| SMA: Bearish | Oct 21, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 14, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 13, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 12, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 8, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 5, 2026 | 4 weeks ago |
Key statistics
- Market cap
- 1.91B
- Enterprise value
- 1.55B
- Trailing P/E
- 0.00
- Forward P/E
- -4.54
- PEG ratio
- 0.00
- Price / sales
- 6.31
- Price / book
- 1.95
- EPS (TTM)
- -1.76
- Beta
- 1.59
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -83.00%
- Revenue (TTM)
- 303.23M
- Revenue growth
- 19582.50%
- Free cash flow
- -38.89M
- Total cash
- 532.73M
- Total debt
- 93.27M
- Return on equity
- -26.08%
- Shares outstanding
- 169.22M
- Short % of float
- 9.72%
- 50-day average
- 10.90
- 200-day average
- 9.50
Analyst view
Consensus: strong buy
- Target (low)
- 15.00
- Target (mean)
- 21.00
- Target (high)
- 30.00
- Strong buy3
- Buy7
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate -0.73157.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | -0.74927 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | 0.3326 | 0.47 | +0.14 | +41.31% |
| May 6, 2026 | Mar 31, 2026 | -0.01 | -0.85 | -0.84 | -8,400.00% |
| Feb 23, 2026 | Dec 31, 2025 | -0.42 | -0.31 | +0.11 | +26.19% |
| Nov 5, 2025 | Sep 30, 2025 | -0.70 | -1.17 | -0.47 | -67.14% |
| Aug 6, 2025 | Jun 30, 2025 | -0.72 | -0.80 | -0.08 | -11.11% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 7, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jun 11, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Jun 3, 2026 | Leerink Partners | main | Outperform | Outperform |
| Mar 4, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Feb 25, 2026 | Barclays | main | Overweight | Overweight |
| Feb 24, 2026 | Morgan Stanley | main | Overweight | Overweight |
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vir.bio
News
- Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors
- Vir Biotechnology: A Big Pharma Collaboration And 2 Clinical Catalysts This Quarter
- Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments
- Vir Biotechnology Signs Up To $1.875B Gilead Deal For 3 Cancer Drug Candidates; Gilead To Pay $65M Cash Upfront And Buy 1,765,486 Shares At $14.16 Each, For A Total Of $25M, Plus Up To $1.785B In Milestones And Royalties
- Vir Biotechnology Announces Collaboration, License Agreement With Gilead To Discover, Engineer Three PRO-XTEN Dual-Masked T-Cell Engager Development Candidates Targeting Selected Solid Tumor-Associated Antigens
- Vir Biotechnology Receives FDA Fast Track Designation For VIR-5500 To Treat Metastatic Castration-Resistant Prostate Cancer
- HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $22
- Vir Biotechnology To Reveal Expanded Phase 2 SOLSTICE Results for Elebsiran And Tobevibart In Hepatitis Delta at AASLD’s The Liver Meeting 2026
- Vir Biotechnology Appoints Aziz Sawaf CFO, Effective Oct. 5
- Vir Biotechnology Q2 EPS $0.47 Beats $0.18 Estimate, Sales $238.946M Beat $216.456M Estimate
Your note
Sign in to keep a note on VIR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DE BACKER MARIANNE | Chief Executive Officer | Sale | Apr 5, 2026 | 1,001,260 |
| DE VERNEUIL VANINA ALEXANDRA HUARD | General Counsel | Sale | Feb 24, 2026 | 112,982 |
| EISNER MARK E | Officer | Sale | Feb 24, 2026 | 154,024 |
| HANLY ANN M | Chief Technology Officer | Sale | Feb 23, 2025 | 117,901 |
| MORE ROBERT J | Director | Stock Award(Grant) | May 26, 2026 | 558,573 |
| O'BYRNE JASON | Chief Financial Officer | Sale | Feb 23, 2026 | 162,615 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 12.22% | 20,678,283 | 233.66M | Jun 29, 2026 |
| Arch Venture Management, Llc | 7.50% | 12,694,163 | 143.44M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 6.79% | 11,495,215 | 129.90M | Jun 29, 2026 |
| SB Investment Advisers (UK) LTD | 6.47% | 10,948,093 | 123.71M | Jun 29, 2026 |
| State Street Corporation | 5.89% | 9,964,151 | 112.59M | Jun 29, 2026 |
| GSK plc | 5.05% | 8,550,954 | 96.63M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.86% | 4,846,948 | 54.77M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.09% | 3,533,092 | 39.92M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.05% | 3,476,669 | 39.29M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.50% | 2,546,144 | 28.77M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.18% | 1,996,625 | 22.56M | Jun 29, 2026 |
| VANGUARD HORIZON FUNDS-Vanguard Strategic Equity Fund | 1.04% | 1,762,412 | 19.92M | Jun 29, 2026 |